A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

To join this study, you need to be an adult between 18 and 70 years old. You must have chronic (long-term) hepatitis D infection, which means you've had it for at least 6 months. If you're already taking medicine for hepatitis B, you need to have been on it for at least 12 weeks, or your hepatitis B virus levels must be very low.

Your liver health is also considered. Your liver enzyme levels (called ALT) should be slightly raised but not too high. You can join if you have no scarring of the liver (non-cirrhotic) or if you have some scarring but your liver is still working well (compensated cirrhosis).

There are also some reasons why you might not be able to join. For example, if you have other serious health problems, certain liver diseases not related to hepatitis B or D, or if you've had severe allergic reactions to medicines in the past. People with a history of certain immune problems or recent alcohol/drug abuse would also not be able to take part.

If you decide to take part in this study, you'll be assigned to either receive the new combination treatment (tobevibart and elebsiran) or to start treatment later. Because it's an "open-label" study, both you and the study team will know which group you are in. You will have regular visits to the clinic where doctors and nurses will check your health, take blood tests, and assess how the treatment is affecting you. You'll also receive the study medication during these visits or be given it to take home. The study will carefully monitor your progress and any side effects. The total duration of your participation, including follow-up appointments after treatment, will be explained in detail by the study team.